BeyondSpring (BYSI) Interest Expenses (2015 - 2026)
BeyondSpring (BYSI) posted Interest Expenses of $256000.0 for Q1 2026, down 81.3% sequentially from $1.4 million in Q4 2025, and down 10.18% YoY from $285000.0 in Q1 2025.
BeyondSpring (BYSI) Interest Expenses (2015 - 2026) Analysis & Trends
BeyondSpring has reported Interest Expenses for 12 years, with the latest figure at $256000.0 in Q1 2026.
- Quarterly Interest Expenses fell 10.18% year-over-year to $256000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 7.04% YoY) and the FY2025 annual result came in at $60.3 million, up 4.24% from the prior year.
- Interest Expenses declined to $256000.0 in Q1 2026 per BYSI's latest filing, from $1.4 million in the prior quarter.
- Over five years, Interest Expenses peaked at $55.8 million in Q4 2023 and troughed at $15000.0 in Q4 2022.
- A 5-year average of $5.5 million and a median of $314000.0 in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses surged 371766.67% in 2023, then tumbled 97.71% in 2024.
- Over 5 years, Interest Expenses stood at $15000.0 in 2022, then soared by 371766.67% to $55.8 million in 2023, then sank by 97.71% to $1.3 million in 2024, then climbed by 6.95% to $1.4 million in 2025, then slumped by 81.3% to $256000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $256000.0, $1.4 million, and $314000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 93.62 Mn |
| 10 | BeyondSpring | 30.64 Mn | 30.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 242,000.00 |
| Jun 30, 2026 | 242,000.00 |
| Mar 31, 2026 | 256,000.00 |
| Mar 31, 2026 | 256,000.00 |
| Dec 31, 2025 | 1.37 Mn |
| Dec 31, 2025 | 1.37 Mn |
| Sep 30, 2025 | 314,000.00 |
| Sep 30, 2025 | 314,000.00 |
| Jun 30, 2025 | 341,000.00 |
| Jun 30, 2025 | 341,000.00 |
| Mar 31, 2025 | 285,000.00 |
| Mar 31, 2025 | 285,000.00 |
| Dec 31, 2024 | 1.28 Mn |
| Dec 31, 2024 | 1.28 Mn |
| Sep 30, 2024 | 269,000.00 |
| Sep 30, 2024 | 269,000.00 |
| Jun 30, 2024 | 296,000.00 |
| Jun 30, 2024 | 296,000.00 |
| Mar 31, 2024 | 363,000.00 |
| Mar 31, 2024 | 363,000.00 |